TriSalus Life Sciences Past Earnings Performance
Past criteria checks 0/6
TriSalus Life Sciences's earnings have been declining at an average annual rate of -7.9%, while the Biotechs industry saw earnings growing at 36.2% annually. Revenues have been growing at an average rate of 40.6% per year.
Key information
-7.85%
Earnings growth rate
75.57%
EPS growth rate
| Biotechs Industry Growth | 17.04% |
| Revenue growth rate | 40.62% |
| Return on equity | -213.27% |
| Net Margin | -127.14% |
| Last Earnings Update | 31 Mar 2026 |
Recent past performance updates
Recent updates
Long Term Embolization Trends And New Indications Will Reshape This Undervalued Medtech Story
Catalysts About TriSalus Life Sciences TriSalus Life Sciences develops and commercializes pressure enabled drug delivery technologies and catheters used in interventional procedures for solid tumors and other vascular conditions. What are the underlying business or industry changes driving this perspective?TriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still Risks
Summary TriSalus Life Sciences aims to achieve positive cash flow by 2025, driven by expanding sales of their TriNav system and reducing operating expenses. The PERIO-03 trial for nelitolimod, a potential treatment for liver-involved cancers, is a key catalyst, with top-line data expected later this year. Financially, TLSI reported a net loss of $30 million for FY 2024, but expects to be EBITDA positive with 50% sales growth in 2025. Despite risks like low cash reserves and potential dilution, I maintain a "buy" rating, contingent on continued sales growth and stable financial reporting. Read the full article on Seeking AlphaTriSalus Life Sciences: Falling Despite Moving Forward Into The Market
Summary TriSalus Life Sciences, Inc. is focusing on developing organ-targeted therapy delivery mechanisms and pairing them with their own drugs. Nelitolimod, a TLR9 activator, is showing promising results in various solid tumor contexts, including liver and pancreatic cancers. Despite financial concerns, TriSalus Life Sciences' growing sales and promising clinical data make them a potential bargain investment when considered for the longer term. Read the full article on Seeking AlphaRevenue & Expenses Breakdown
How TriSalus Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 45 | -57 | 51 | 15 |
| 31 Dec 25 | 45 | -70 | 50 | 15 |
| 30 Sep 25 | 40 | -71 | 50 | 15 |
| 30 Jun 25 | 36 | -33 | 47 | 14 |
| 31 Mar 25 | 32 | -30 | 44 | 15 |
| 31 Dec 24 | 29 | -33 | 44 | 18 |
| 30 Sep 24 | 27 | -59 | 44 | 22 |
| 30 Jun 24 | 25 | -58 | 42 | 28 |
| 31 Mar 24 | 22 | -68 | 41 | 30 |
| 31 Dec 23 | 19 | -64 | 36 | 30 |
| 30 Sep 23 | 16 | -53 | 33 | 28 |
| 30 Jun 23 | 15 | -59 | 30 | 24 |
| 31 Mar 23 | 13 | -51 | 27 | 22 |
| 31 Dec 22 | 12 | -50 | 25 | 21 |
| 30 Sep 22 | 12 | -32 | 22 | 19 |
| 31 Dec 21 | 8 | -29 | 17 | 14 |
| 31 Dec 20 | 5 | -32 | 13 | 16 |
Quality Earnings: TLSI is currently unprofitable.
Growing Profit Margin: TLSI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TLSI is unprofitable, and losses have increased over the past 5 years at a rate of 7.9% per year.
Accelerating Growth: Unable to compare TLSI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TLSI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (54.5%).
Return on Equity
High ROE: TLSI has a negative Return on Equity (-213.27%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/05 10:08 |
| End of Day Share Price | 2026/06/05 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TriSalus Life Sciences, Inc. is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Plovanic | Canaccord Genuity |
| Justin Walsh | JonesTrading Institutional Services, LLC |
| Frank Takkinen | Lake Street Capital Markets, LLC |